Bifidobacterium animalis is a bacterial species found in some dog probiotics sold in the UK, and the honest position is this: one small canine trial suggests a specific strain shortened acute diarrhoea by roughly two and a half days, and almost everything else you will read about it comes from human, dairy or laboratory work. If you are standing in a pet shop in Basingstoke holding a tub with "Bifidobacterium animalis" on the label, the useful question is not whether the species is good, but which subspecies and which strain you are actually buying, and whether the product legally sits as a complementary feed rather than a medicine. This page answers both, in the UK regulatory context, and flags where the evidence runs out.
One species, two subspecies, and why UK labels blur them
Bifidobacterium animalis has two recognised subspecies: subsp. animalis and subsp. lactis. That distinction matters more than most marketing copy admits. The strains familiar from human yoghurt and supplements sold on the high street, including BB-12, are subsp. lactis. They were selected for human gut conditions and for surviving dairy fermentation, not for the canine gastrointestinal tract.
The single canine-specific strain with a published clinical trial behind it is AHC7. O'Mahony D and colleagues documented that AHC7 was isolated from canine gastrointestinal tissue (Veterinary Microbiology, 2009;139(1-2):106-112, PMID 19523775). Canine origin is not a guarantee of benefit, but it is a reasonable selection criterion and it is the sort of provenance detail a UK label almost never gives you.
A label that says only "Bifidobacterium animalis" is telling you the species and withholding the two pieces of information that determine whether any published research applies: the subspecies and the strain code.
What the one canine trial actually found
Kelley RL and colleagues published the trial in Veterinary Therapeutics, 2009;10(3):121-130 (PMID 20037966). Thirty-one dogs with acute idiopathic diarrhoea were randomised, with 13 receiving the probiotic. The strain was AHC7, given at 2 x 10^10 CFU per day. Time to resolution was 3.9 +/- 2.3 days in the probiotic group against 6.6 +/- 2.7 days in the control group, P<0.01. Metronidazole was given to 38.5% of the probiotic group and 50.0% of the control group.
Read that carefully before it gets oversold to you. Thirteen dogs on treatment is a small group. The condition studied was acute idiopathic diarrhoea, the self-limiting sort that a practice sees on a Monday morning after a weekend of scavenging, not chronic enteropathy, not food-responsive disease, not inflammatory bowel disease. And the metronidazole difference was a numerical trend in a tiny sample, not a demonstrated antibiotic-sparing effect.
The mechanistic work most often cited alongside it is O'Mahony D et al., BMC Immunology, 2010;11:63 (PMC3016395), which reported attenuation of NF-kB signalling after a Salmonella typhimurium challenge. That was a murine study. It was carried out in mice, not dogs, and it explains a plausible mechanism rather than proving a clinical outcome in your spaniel.
The wider caution comes from Jensen AP and Bjornvad CR in the Journal of Veterinary Internal Medicine, 2019;33(5):1849-1864 (PMID 31313372), whose systematic appraisal found most canine probiotic trials sit at moderate-to-high risk of bias. That verdict covers this literature as a whole, including the trial above.
The UK regulatory position, and why you cannot buy AHC7 here
This is where a UK article has to part company with American advice. In Great Britain, probiotics for dogs are regulated as feed, not as veterinary medicines. A product sold for gut support is a complementary feed under assimilated EU feed law, overseen through DEFRA and enforced locally by Trading Standards. It is not assessed by the Veterinary Medicines Directorate, because it is not making a medicinal claim, and it must not make one.
Within feed law there is a separate register of authorised zootechnical feed additives, and it is strain-specific. Enterococcus faecium NCIMB 10415 holds that kind of authorisation for dogs. Bifidobacterium animalis does not sit on the GB authorised-additive list in the same way. A UK product carrying it is therefore selling it as a feed ingredient in a complementary feed, which is lawful, rather than as an authorised additive with an evaluated dossier behind it.
The AHC7 story makes the point sharply. When EFSA's FEEDAP panel reviewed the additive behind Prostora Max, the AHC7 product, it concluded that the antibiotic-resistance qualification was not met because of clindamycin resistance. QPS status could therefore not be applied, and the additive was not authorised. That, not availability or price, is the reason a UK owner will not find AHC7 on a British shelf. If you have read the Kelley trial and gone looking for the exact product used in it, you are not missing something. It is not sold here.
The practical consequence: for a UK buyer, the strain with the canine evidence is unobtainable, and what remains on sale is other B. animalis subsp. lactis strains with human or dairy pedigrees. Anyone who tells you those inherit the trial result is guessing.
How to read a British label without being misled
| What the label says | What it actually tells you | How much research applies |
|---|---|---|
| "Probiotics" or "beneficial bacteria" | Nothing identifiable | None |
| Bifidobacterium animalis (species only) | Species, but not which of the two subspecies | Very little; you cannot match it to any trial |
| B. animalis subsp. lactis | Subspecies identified, strain withheld | Narrows it, but effects are strain-specific |
| B. animalis subsp. lactis BB-12 (or similar code) | Full identification; traceable to published work | Applies only to that strain, mostly human data |
| "Proprietary blend, 5 billion CFU" | A total count with no per-strain breakdown | None; a token strain and a bulking strain look identical |
| CFU "at time of manufacture" | Count at packing, not at feeding | Says nothing about what survives the shelf |
Label accuracy in this category has a documented history. Weese JS and Martin H, writing in the Canadian Veterinary Journal, 2011;52(1):43-46 (PMID 21461205), found that only 4 of 15 products met their stated CFU counts, and that the organism name was misspelled on 7 of 22 labels. A misspelt genus on the tub is a legitimate reason to put it back. It suggests nobody in that supply chain is checking the microbiology.
If you want the broader comparison across organisms before deciding, our guide to the best probiotic for dogs sets out how the species differ. For the underlying species detail without the UK regulatory layer, see bifidobacterium animalis for dogs. The neighbouring organisms have their own UK pages: lactobacillus for dogs UK, enterococcus faecium for dogs UK, and saccharomyces boulardii for dogs UK.
The Boots and Holland & Barrett temptation
Human Bifidobacterium capsules are cheap, widely stocked, and sitting on a shelf you already walk past. Several reasons to be careful before repurposing one.
- Xylitol. Chewable and flavoured human supplements are frequently sweetened with xylitol, which is seriously toxic to dogs. Read the full ingredients list, not the front of the box. If xylitol is present, it is not a question of dose adjustment. Do not give it.
- Doses set for adult humans. A capsule formulated for a 70 kg person carries no meaningful guidance for a 6 kg terrier, and the research does not tell us how to scale it.
- Human-selected strains. Subsp. lactis strains in high-street products were chosen for human guts. Canine relevance is assumed, not shown.
- Excipients. Flavourings, sugar alcohols and fillers are cleared for human use, and that clearance says nothing about dogs.
Antimicrobial stewardship, and why your vet may raise this first
BSAVA's PROTECT ME framework has pushed UK practices hard towards not reaching for antibiotics in self-limiting gastrointestinal upset. That is why "could we try a probiotic rather than another course of metronidazole" is a live conversation in British consulting rooms rather than a fringe one. It is a reasonable question to put to your RCVS-registered veterinary surgeon.
Ask it as a question, though, not as a plan. The metronidazole figures in the Kelley trial, 38.5% against 50.0%, were not designed to test antibiotic sparing and cannot carry that weight. Never stop a prescribed course because you have started a supplement.
A realistic timeline
Expectation-setting is where most probiotic advice fails owners.
- Days 1 to 7. In acute self-limiting upset, this is the window where the trial saw a difference. Anything you observe here may also be the episode resolving on its own, which is what "self-limiting" means.
- Week 2. Stool consistency and frequency are the only things worth tracking. Write them down, because memory flatters whatever you have just bought. No change at all by now, in an acute episode, is a reason to ring the practice.
- Week 4. If you started for general maintenance rather than an acute episode, this is the earliest point at which a pattern rather than a coincidence becomes visible. Still no measurable change means the honest conclusion is that it is not doing anything for this dog.
- Week 6. A decision point, not a milestone. Continue because you can point to something specific, or stop. Indefinite continuation on the basis of hope is how people spend money on nothing.
Colonisation is not the goal and generally does not happen. Effects while feeding do not imply permanent change to the microbiota. Suchodolski JS, in The Veterinary Journal, 2016;215:30-37 (PMID 27160005), sets out how dysbiosis in dogs should be interpreted, and the short version is that a shifted microbial profile is a finding needing clinical context, not a diagnosis a supplement corrects.
When to ring your vet instead of reaching for a supplement
Get on the phone to the practice, or to the out-of-hours service, if any of these apply.
- Blood in the faeces, or black tarry faeces
- Repeated vomiting, or an inability to keep water down
- Diarrhoea lasting more than 48 hours, or any diarrhoea in a puppy, a senior dog, or a dog with an existing condition
- Lethargy, collapse, pale gums, or a distended or painful abdomen
- Unproductive retching, which is an emergency in deep-chested breeds
- Weight loss, or diarrhoea that keeps returning over weeks
- Any suspicion of a swallowed foreign object, toxin or human medication
- The dog is immunocompromised or seriously unwell, in which case live bacterial products should only be given on veterinary advice
What we will not claim
Stating this plainly is part of selling a feed product honestly under UK rules.
- We do not claim B. animalis treats, prevents or cures any disease in dogs. A complementary feed making a medicinal claim would be an unlicensed medicine.
- We do not claim the Kelley result transfers to other strains. It was AHC7, at 2 x 10^10 CFU per day, in acute idiopathic diarrhoea.
- We do not claim a probiotic reduces the need for antibiotics. That decision belongs to your veterinary surgeon.
- We do not present the NF-kB finding as a canine result. It was a murine study.
- We do not claim benefit in chronic enteropathy, allergy, anxiety or immune function. Research does not strongly prove those claims in dogs.
- We do not claim any product permanently alters your dog's microbiota.
Choosing sensibly, and where our product sits
Judge a UK product on four things: full strain identification, CFU guaranteed to end of shelf life rather than at manufacture, a manufacturer who will answer a direct email about strain provenance, and a format your dog will actually take every day. That last point is not trivial. A chew the dog reliably eats beats an unused liquid sitting at the back of a cupboard, and the reverse is equally true for a fussy dog who spits out chews. Compliance is the variable you control.
Our own liquid probiotic for dogs is a complementary feed, formulated so it can be measured against food for dogs who refuse tablets and chews. We do not publish a CFU figure we cannot stand behind, and we will not tell you it reproduces the AHC7 trial, because no product sold in the UK can. More on how we approach formulation at Pure Majesty Pets.
Frequently asked questions
Is Bifidobacterium animalis safe for dogs in the UK?
It is generally well tolerated in healthy dogs, with mild wind or looser stools sometimes reported in the first few days. Dogs that are immunocompromised, seriously unwell, or have a central venous line should only be given live bacterial products under veterinary direction.
Can I give my dog a human Bifidobacterium capsule from Boots?
Check for xylitol first, and do not use the product if it contains any, because xylitol is seriously toxic to dogs. Beyond that, human capsules use adult-set doses and human-selected subsp. lactis strains, so a canine-formulated product is the more sensible choice.
Which subspecies should I look for on the label?
The two are subsp. animalis and subsp. lactis. Most commercial strains, including BB-12, are subsp. lactis. What matters more is the strain code, because published effects belong to strains rather than to species.
Why can't I buy the strain used in the dog study?
The trial used AHC7. EFSA's FEEDAP panel, reviewing the AHC7 product Prostora Max, concluded the antibiotic-resistance qualification was not met because of clindamycin resistance, so QPS could not be applied and the additive was not authorised. That is why it is not on UK shelves.
Is a dog probiotic a veterinary medicine in the UK?
No. It is sold as a complementary feed, regulated as feed through assimilated EU feed law and enforced by Trading Standards. It is not assessed by the Veterinary Medicines Directorate and must not carry medicinal claims.
How long before I see anything?
In acute self-limiting diarrhoea the trial difference appeared within the first week. For general maintenance, give it four weeks with written notes on stool consistency, and treat week six as a decision point to continue or stop.
Scientific References
- Kelley RL, et al. Veterinary Therapeutics. 2009;10(3):121-130. PMID 20037966
- O'Mahony D, et al. Veterinary Microbiology. 2009;139(1-2):106-112. PMID 19523775
- O'Mahony D, et al. BMC Immunology. 2010;11:63 (murine study). PMC3016395
- Weese JS, Martin H. Canadian Veterinary Journal. 2011;52(1):43-46. PMID 21461205
- Jensen AP, Bjornvad CR. Journal of Veterinary Internal Medicine. 2019;33(5):1849-1864. PMID 31313372
- Suchodolski JS. The Veterinary Journal. 2016;215:30-37. PMID 27160005
Disclaimer. This article is for information only and is not veterinary advice. Pure Majesty Pets products are complementary feeds for dogs. They are not veterinary medicines, have not been assessed by the Veterinary Medicines Directorate, and are not intended to diagnose, treat, prevent or cure any disease. If your dog is unwell, consult an RCVS-registered veterinary surgeon at your own practice. Do not stop or alter prescribed treatment on the basis of anything written here.